Overview
Brett Zirkle, Ph.D., works with life sciences companies to develop patent portfolios that support platform and product development, capital investment, and commercialization. His practice includes patent prosecution, company- and investor-side patent matters, and related strategic counseling on life science biologics and platform technologies. Driven by a commitment to helping life sciences companies make breakthroughs and change lives, Brett brings a clear, practical approach to translating innovative science into IP strategy — developing patent portfolios that fuel growth and impact.
Life Sciences & Biotechnology
Brett advises discovery, preclinical and clinical-stage companies across a broad range of life sciences and biotechnologies — including antibodies, gene therapies, cell therapies, protein-based therapeutics, and single-cell and molecular assay platform technologies — on patent matters to support patent transactional due diligence in connection with financings, acquisitions, licensing, collaborations and partnerships.
Patent Counseling
An experienced patent agent, Brett helps companies develop patent strategies and portfolios that protect innovation and enable key transactions. Combining a deep understanding of clients’ technology with strategic scientific insight, he works with companies to drive transformation of breakthrough science into patent assets that support growth across all stages.
Representative Experience
Brett’s experience working with life sciences companies and venture capital firms includes developing and implementing patent strategies and patent prosecution for product development, licensing, venture financings and M&A transactions.
Technical Experience
Brett’s areas of technical experience include:
- Biologics
- Antibodies
- Antibody-drug conjugates
- Protein therapeutics
- Peptide therapeutics
- Gene therapies
- Cell therapies
- Molecular and cellular assay technologies
Prior Life Sciences Experience
Before joining Faegre Drinker, Brett worked in the intellectual property and life sciences group of a multinational law firm in its San Diego office. Prior to University of San Diego School of Law, Brett earned his Ph.D. in genetic, molecular and cellular biology at Keck School of Medicine of the University of Southern California, where his doctoral research focused on the structural biology, biochemistry and genomics of immune response proteins, including antibodies and DNA-editing enzymes. Before making the move to Los Angeles, Brett was an Intramural Research Award Fellow at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases within the National Institutes of Health, where his research focused on HIV-antibody structural biology and biochemistry. He was also the recipient of a NASA West Virginia Space Grant for research in the field of molecular biology.
Personal Interests
Brett enjoys reading, cooking, making and drinking the best coffee, and spending time with his wife and kids.
Related Legal Services
Related Industries
Credentials
Bar Admissions
Not admitted to practice in California
U.S. Patent and Trademark Office
Education
University of San Diego School of Law
J.D. (2023)
University of Southern California - Keck School of Medicine
Ph.D. in Genetic, Molecular, and Cell Biology (2019)
Shepherd University
B.S. in Biology (2009)
Insights & Events
Latest
News
Other Perspectives
- Understanding the Structural Basis of HIV-1 Restriction by the Full Length Double-Domain APOBEC3G
Co-author, 11 Nature Communications 632 (2020) - Antigenic Variations of Recent Street Rabies Virus
Co-author, 8 Emerging Microbes & Infections 1584 (2019) - Understanding the Structure, Multimerization, Subcellular Localization, and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H
Co-author, 8(1) Scientific Reports 3763 (2018) - Structural Determinants of APOBEC3B Non-catalytic Domain for Molecular Assembly and Catalytic Regulation
Co-author, 45(12) Nucleic Acids Research 7494-7506 (2017) - N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03
Co-author, 69(3) Journal of Acquired Immune Deficiency Syndromes 270-7 (2015) - Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6
Co-author, 88(5) Journal of Virology 2426-41 (2014) - Early Stages of Induction of Anterior Head Ectodermal Properties in Xenopus Embryos Are Mediated by Transcriptional Cofactor ldb1
Co-author, 243(12) Developmental Dynamics 1606-18 (2014)